Government-Owned Inventions; Availability for Licensing, 76741-76743 [2011-31553]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 236 / Thursday, December 8, 2011 / Notices
Newborns and Children (Advisory
Committee), as authorized by Public Law
106–310, which added section 1111 of the
Public Health Service Act, codified at 42
U.S.C. 300b–10, was established by Congress
to advise the Secretary in connection with
the development of newborn screening
activities, technologies, policies, guidelines
and programs for effectively reducing
morbidity and mortality in newborns and
children having or at risk for heritable
disorders. Recommendations for screenings
that are adopted by the Secretary are
included in the Recommended Uniform
Screening Panel (RUSP), which forms a part
of the Comprehensive Guidelines supported
by the Health Resources and Services
Administration. Pursuant to section 2713 of
the Public Health Service Act, codified at 42
U.S.C. 300gg–13, non-grandfathered health
plans are required to cover screenings
provided for in the Comprehensive
Guidelines without charging a co-payment,
co-insurance, or deductible for plan years (in
the individual market these are known as
policy years) beginning on or after the date
that is one year from the Secretary’s adoption
of a screening(s). The Advisory Committee
also provides advice and recommendations
concerning grants and projects authorized
under section 1109 of the Public Health
Service Act (42 U.S.C. 300b–8).
Agenda: The meeting will include: (1) An
orientation for all new Committee members
including overviews of the Department of
Health and Human Services, the Health
Resources and Services Administration
(HRSA), and the Maternal and Child Health
Bureau; (2) the history of the Advisory
Committee; (3) an overview of the
authorizing legislation for the Advisory
Committee; (4) updates from the Nomination
and Prioritization workgroup, Public Health
Impact Matrix workgroup and the Evidence
Review workgroup; and (5) presentations on
the continued work and reports of the
Advisory Committee’s subcommittees:
Laboratory Standards and Procedures;
Follow-up and Treatment; and Education and
Training. Tentatively, the Advisory
Committee is expected to review and/or vote
on the following items: (1) Forwarding the
22q11 condition nomination package to the
Evidence Review Workgroup for further
evaluation; (2) reviewing the draft Public
Health Impact Matrix; (3) forwarding the
Hyperbilirubinemia condition nomination to
the Public Health Impact Workgroup for
further evaluation; (4) reviewing the report
on Linking Birth Certificates and Serial
Numbers; and (5) reviewing the report on
Implementing Point of Care Newborn
Screening.
Proposed agenda items are subject to
change as priorities dictate. The Agenda,
Committee Roster and Charter, presentations,
and meeting materials can be found at the
home page of the Advisory Committee’s Web
site at https://www.hrsa.gov/
heritabledisorderscommittee/.
Public Comments: Members of the public
can submit written comments and/or present
oral comments during the public comment
periods of the meeting. Time for public
comments has been scheduled to occur
during the afternoon of January 26, 2012.
VerDate Mar<15>2010
15:59 Dec 07, 2011
Jkt 226001
Those individuals who want to make oral
comments are requested to register online by
Monday, January 23, 2012 at https://
altarum.cvent.com/event/sachdncjan2012. In
order to be considered, written comments
should be emailed no later than Tuesday,
January 24, 2012. All comments, whether
oral or written, should contain the name,
address, telephone number, and any
professional or business affiliation of the
author. Groups having similar interests are
requested to combine their comments and
present them through a single representative.
Submit written comments to Maureen Ball,
Meetings Coordinator, Conference and
Meetings Management, Altarum Institute,
1200 18th Street NW., Suite 700,
Washington, DC 20036. Comments may also
be faxed (202) 785–3083 or emailed
(conferences@altarum.org). If you have
additional questions regarding the
submission of comments, please contact Ms.
Ball at (202) 828–5100.
Contact Person: Anyone interested in
obtaining other relevant information should
contact or write to Debi Sarkar, Maternal and
Child Health Bureau, Health Resources and
Services Administration, Room 18A–19,
Parklawn Building, 5600 Fishers Lane,
Rockville, Maryland 20857; telephone: (301)
443–1080; email: dsarkar@hrsa.gov. More
information on the Advisory Committee is
available at https://mchb.hrsa.gov/
heritabledisorderscommittee.
Dated: December 2, 2011.
Reva Harris,
Acting Director, Division of Policy and
Information Coordination.
[FR Doc. 2011–31522 Filed 12–7–11; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
76741
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Novel NSAIDs for the Treatment of
Human Diseases
Description of Technology: The
invention relates to novel compounds
which are hybrids between two
moieties, i.e. non-steroidal antiinflammatory drugs (NSAID) and
Nitroxyl (HNO) releasing agents as well
as Nitroxide (an antioxidant and
superoxide scavenger). Such modified
NSAIDs have shown to be advantageous
to conventionally used NSAID, as their
toxicity is significantly reduced and
they can thus be used in medical
treatment for extended periods of time
without severe side effects. The adverse
side effects (i.e. heart attack, thrombosis
and severe gut toxicity) presented by
conventional NSAIDs are well
documented and some of them (i.e.
Vioxx) were therefore withdrawn from
the market. The present compounds
may alleviate these problems, and may
render more anti-inflammatory agents
suitable for human use. The HNO
releasing moiety of these novel
compounds will expand the medical
utility of these compounds, as HNO
releasing agents possess anticancer
activity as well as good antioxidant
activities, a property that is beneficial
for a variety of human diseases,
including acute and chronic
inflammation. In summary, the hybrid
compounds provided in the invention
can be useful in treatment of variety of
human diseases (i.e. inflammatory
diseases, heart diseases and cancer)
with relatively low level of side effects.
Potential Commercial Applications:
The drugs of this invention will be
useful in treatment of anti-inflammatory
diseases, and as therapeutic or
preventative drugs for cardiovascular
diseases, diabetes and cancer.
Competitive Advantages: The hybrid
structure of the present drugs will
render them useful in therapy and
prevention of a wide variety of
disorders, with reduced toxicity.
Development Stage: In vitro data
available.
Inventors: David A. Wink et al. (NCI).
Publication: Flores-Santana W et al.
Redox-Modified Non-Steroidal AntiInflammatory Drugs as Potential AntiCancer Agents with the SOD Mimetic
Nitroxide. Br J Pharmacol. 2011 Jun 9;
doi: 10.1111/j.1476–5381.2011.01527.x
(Epub ahead of print). [PMID 21658022].
Intellectual Property: HHS Reference
No. E–131–2011/0—U.S. Provisional
E:\FR\FM\08DEN1.SGM
08DEN1
76742
Federal Register / Vol. 76, No. 236 / Thursday, December 8, 2011 / Notices
Application No. 61/472,770 filed 07 Apr
2011.
Licensing Contact: Betty Tong, Ph.D.;
(301) 594–6565; tongb@mail.nih.gov.
Fibroblast Growth Factor Receptor 1
(Fgfr1) Conditional Knock Out Mouse
Description of Technology: Scientists
at NIDDK have developed a fibroblast
growth factor receptor 1 (Fgfr1)
conditional knock out mouse. Fgfr1 is a
member of the Fgfr family of
transmembrane protein receptors with
intrinsic tyrosine kinase activity. Fgfr1
is important in multiple biological
processes, including mesoderm
induction and patterning, cell growth
and migration, organ formation and
bone growth. Fgfr1 is highly expressed
in central nervous system tissues and
plays a critical role in proliferation,
migration, and survival of neurons and
glial cells. Additionally, overexpression
of Fgfr1 has been associated with
mammary gland transformation and
may be crucial for the development of
some cancers. The Fgfr1 conditional
knockout mouse can be used to study
development and biological processes in
a variety of tissues and can provide
information on signaling pathways that
interact with Fgfr1 to induce genes
important for critical cellular events,
such as proliferation, differentiation,
adhesion, movement, survival, and
transformation.
Potential Commercial Applications
• Basic research tool to investigate
intracellular pathways dependent on
Fgfr1.
• Tool to study skeletal and neural
development.
• Model of stress-related
environments such as bone fractures or
tumorigenic induction.
mstockstill on DSK4VPTVN1PROD with NOTICES
Competitive Advantages
• Unlike Fgfr1 null mice that are
embryonic lethal, Fgfr1 conditional
knockout mice are viable and can be
used to study the role of Fgfr1 in tissue
and organ development.
• Mice carrying the Fgfr1 conditional
knockout mutation can be cross-bred
using, for example, Cre-expressing mice
to generate tissue specific knockouts of
Fgfr1 and used for more detailed tissue
studies of Fgfr1 signaling.
Development Stage: In vivo data
available (animal).
Inventor: Chu-Xia Deng (NIDDK).
Publication: Xu X, Qiao W, Li C, Deng
CX. Generation of Fgfr1 conditional
knockout mice. Genesis. 2002
Feb;32(2):85–86. [PMID 11857785].
Intellectual Property: HHS Reference
No. E–071–2011/0—Research Tool.
VerDate Mar<15>2010
15:59 Dec 07, 2011
Jkt 226001
Patent protection is not being pursued
for this technology.
Licensing Contact: Jaime M. Greene;
(301) 435–5559;
greenejaime@mail.nih.gov.
Biomarkers for Cancer-Related Fatigue
and Their Use in the Management of
Such Fatigue (CRF)
Description of Technology: The
invention relates to the diagnosis and
management of cancer-related fatigue
(CRF). More specifically the invention
relates to identification and
measurement of a single Biomarker or a
group of biomarkers (e.g. genes) that are
associated with cancer related fatigue.
The identification and measurement of
such biomarkers can be utilized in the
diagnosis and management of fatigue
and may facilitate the development of
therapy for such fatigue. In particular,
the invention provides for a method of
diagnosing a subject with CRF by
detecting expression of at least one gene
associated with CRF in a sample
obtained from the subject; and
comparing expression of the gene to a
control. The invention also describes a
method of treating a patient with CRF
by administering to the subject an agent
that alters expression or activity of a
gene associated with CRF. Further
provided in the invention is array that
includes a plurality of genes associated
with CRF, such as TNFRSF25, SLC6A8,
OGT, SNCA, APBA2, CASK, OR2W3,
MYL4, IL7R, ARHGEF10 and ITGA6.
Some of these genes are over expressed
in a CRF patient (e.g., SNCA and
SLC6A8) while others (e.g., IL7R,
ARHGEF10) are under expressed. The
array can provide detailed and
comprehensive information that can
result in improved diagnostics and in
increased options for therapeutic
treatment.
Potential Commercial Applications:
Diagnostics and therapeutics of cancerrelated fatigue.
Competitive Advantages: The
technology provides for an array of
multiple biomarkers, all associated with
CRF. Thus it may offer a more detailed
and accurate diagnosis of CRF as well as
a larger number of therapeutic options.
Development Stage
• In vitro data available (animal).
• In vivo data available (human).
Inventor: Leorey Saligan (NINR).
Intellectual Property: HHS Reference
E–280–2010/0 — U.S. Provisional
Application No. 61/442,605 filed 14 Feb
2011.
Licensing Contact: Betty Tong, Ph.D.;
(301) 594–6565; tongb@mail.nih.gov.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Characterizing Compartment
Distributions From Diffusion Weighted
Magnetic Resonance (MR) Data
Description of Technology: The
National Institutes of Health seeks
licensees with MR software expertise to
commercialize a method of imaging the
structural and dimensional
characteristics (microstructure) of
microscopic specimens. Microstructure
is elucidated using MR scanning and the
diffusion weighted MR signal is
transformed into statistical moments of
the underlying compartment size
distribution associated with restricted
diffusion. Essentially, the method
includes the steps of: (1) Acquiring
diffusion weighted image or
spectroscopic data, (2) applying the new
modeling framework relating pore size
distribution to the diffusion weighted
(DW) data, and (3) using this framework
to estimate moments of the pore
diameter distribution from the DW data.
Potential Commercial Applications:
Examination of tissue/cellular
microstructures.
Competitive Advantages: Refined
imaging.
Development Stage: In vitro data
available.
Inventors: Evren Ozarslan and Peter J.
Basser (NICHD).
Publications
1. Assaf Y, et al. AxCaliber: a method for
measuring axon diameter distribution from
diffusion MRI. Magn Reson Med. 2008
Jun;59(6):1347–1354. [PMID 18506799].
2. Shemesh N, et al. Accurate noninvasive
measurement of cell size and compartment
shape anisotropy in yeast cells using doublepulsed field gradient MR. NMR Biomed. 2011
July 22. E-pub ahead of print, doi: 10.1002/
nbm.1737. [PMID 21786354].
3. Ozarslan E, et al. NMR characterization
of general compartment size distributions.
New J Phys. 2011 Jan;13:15010. [PMID
21709780].
4. Komlosh ME, et al. Pore diameter
mapping using double pulsed-field gradient
MRI and its validation using a novel glass
capillary array phantom. J Magn Reson. 2011
Jan;208(1):128–135. [PMID 21084204].
5. Nevo U, et al. A system and
mathematical framework to model shear flow
effects in biomedical DW-imaging and
spectroscopy. NMR Biomed. 2010
Aug;23(7):734–744. [PMID 20886564].
6. Shemesh N, et al. From single-pulsed
field gradient to double-pulsed field gradient
MR: gleaning new microstructural
information and developing new forms of
contrast in MRI. NMR Biomed. 2010
Aug;23(7):757–780. [PMID 20690130].
7. Shemesh N, et al. Noninvasive bipolar
double-pulsed-field-gradient NMR reveals
signatures for pore size and shape in
polydisperse, randomly oriented,
inhomogeneous porous media. J Chem Phys.
2010 Jul 28;133(4):044705. [PMID 20687674].
E:\FR\FM\08DEN1.SGM
08DEN1
Federal Register / Vol. 76, No. 236 / Thursday, December 8, 2011 / Notices
Intellectual Property: HHS Reference
No. E–273–2010/0—U.S. Provisional
Patent Application No. 61/522,421 filed
11 Aug 2011.
Related Technologies
• HHS Reference No. E–079–2003/
0—U.S. Patent 7,643,863 issued 05 Jan
2010; International Patent Application
PCT/US2004/22027 filed 08 Jul 2004,
which published as WO 2005/012926
on 10 Feb 2005.
• HHS Reference No. E–079–2003/
1—U.S. Patent Application 12/114,713
filed 02 May 2008.
Licensing Contact: Michael
Shmilovich, Esq.; (301) 435–5019;
mish@codon.nih.gov.
One Step Fluorine-18 Peptide Labeling
Strategy of Biological Substrates
Description of Technology: A one-step
process is now available for licensing
that allows direct 18F labeling of any
biological substrate that is modified
with 4-nitro-3-trifluoromethyl arene.
Normally, 18F labeling requires several
time-consuming radio synthesis steps
using prosthetic groups, resulting in a
low labeling yield. Other attempts at
one step labeling methods have also
shown relatively low yields.
This new process eliminates timeconsuming radiosynthesis steps and
associated low labeling yields with a
single step process that displaces a nitro
group in an arene. Relatively low
amounts of precursor and short time
radiosynthesis times are required
compared to direct peptide-labeling.
Higher yields by this simplified process
improve time and cost efficiencies and
may make 18F labeling more amenable
for automation.
Potential Commercial Applications
• Radiological imaging.
• Radiological diagnosis.
• Radiological therapy.
Competitive Advantages
• Significantly shorter reaction and
synthesis times.
• Lower amounts of precursor
required.
• Relatively high yield of specific
activity product.
mstockstill on DSK4VPTVN1PROD with NOTICES
Development Stage
• Early-stage.
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: Xiaoyuan (Shawn) Chen
and Orit J. Weiss (NIBIB).
Publication: Jacobson O, et al. Rapid
and simple one-step F–18 labeling of
peptides. Bioconjug Chem. 2011 Mar
16;22(3):422–428. [PMID 21338096].
VerDate Mar<15>2010
15:59 Dec 07, 2011
Jkt 226001
Intellectual Property: HHS Reference
No. E–238–2010/0—U.S. Provisional
Patent Application No. 61/429,671 filed
04 Jan 2011.
Licensing Contact: Tedd Fenn; (301)
435–5031; Tedd.Fenn@NIH.gov.
Collaborative Research Opportunity:
The NIBIB is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the technology for One
Step Fluorine-18 Peptide Labeling
Strategy of Biological Substrates. For
collaboration opportunities, please
contact Shawn Chen, Ph.D. at
shawn.chen@nih.gov.
Dated: December 2, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–31553 Filed 12–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Licensing and Collaborative Research
Opportunity: Chemotoxins for
Targeted Treatment of Diseased Cells
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patents and patent applications
listed below may be obtained by
contacting Patrick McCue, Ph.D. at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852; telephone: (301) 496–7057; email: McCuepat@mail.nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Inquiries related to Collaborative
Research Opportunities may be directed
to Nikki Guyton, Ph.D. at the
Technology Transfer Center, National
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
76743
Cancer Institute, 6120 Executive
Boulevard, Suite 450, Rockville, MD
20852; telephone: (301) 435–3101;
email: darackn@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Technology
Researchers at the National Institute
on Aging (NIA) have developed a
straightforward method to elicit
immune responses to specific cancers
and AIDS by using a chemoattractantbased antigen delivery strategy. The
strategy uses formulations composed of
chemokines fused to toxic moieties (aka
‘‘chemotoxins’’) to preferentially and
specifically eliminate chemokine
receptor-expressing cells. The method
uses the natural ability of the
chemokines to stimulate measurable
and improved humoral and immune
responses.
• Chemokines can be of viral or
microbial (B–Defensin) origin.
• This method can also be used to
cause inflammation to specifically target
immune cells to increase
immunogenicity for malignant tumors
using SPANX–B and Laminin tumor
antigens.
Potential Commercial Applications
• A potential immunotherapeutic
antigen for the treatment of several
malignancies including lymphoma,
breast, lung, and ovarian.
• Use as a monoclonal antibody.
• Antigens, such as SPANX–B and
Laminin, can also be used as prognostic
and diagnostic agents for the monitoring
of disease.
Competitive Advantages
• In contrast to recombinant proteins,
these small peptides can be more easily
manufactured.
• They help to facilitate the activation
of cells in a more specific and
therapeutically effective way.
• Active immune system will do a
better job attacking cancer cells.
• Simple and less invasive.
Collaborative Research Opportunity
The National Institute on Aging (NIA)
is seeking parties interested in
collaborative research to further
evaluate or commercialize effective
vaccines that target bacterial, viral, or
tumor antigens. Any or all of the
inventions in this announcement are
available for co-development and
collaboration.
Intellectual Property and
Developmental Status
• Viral Chemokine Antigen Fusion
Proteins (E–194–2000).
Patent Status: US Patent No.
6,562,347 issued 13 May 2003.
E:\FR\FM\08DEN1.SGM
08DEN1
]]>Agencies
[Federal Register Volume 76, Number 236 (Thursday, December 8, 2011)]
[Notices]
[Pages 76741-76743]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31553]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Novel NSAIDs for the Treatment of Human Diseases
Description of Technology: The invention relates to novel compounds
which are hybrids between two moieties, i.e. non-steroidal anti-
inflammatory drugs (NSAID) and Nitroxyl (HNO) releasing agents as well
as Nitroxide (an antioxidant and superoxide scavenger). Such modified
NSAIDs have shown to be advantageous to conventionally used NSAID, as
their toxicity is significantly reduced and they can thus be used in
medical treatment for extended periods of time without severe side
effects. The adverse side effects (i.e. heart attack, thrombosis and
severe gut toxicity) presented by conventional NSAIDs are well
documented and some of them (i.e. Vioxx) were therefore withdrawn from
the market. The present compounds may alleviate these problems, and may
render more anti-inflammatory agents suitable for human use. The HNO
releasing moiety of these novel compounds will expand the medical
utility of these compounds, as HNO releasing agents possess anticancer
activity as well as good antioxidant activities, a property that is
beneficial for a variety of human diseases, including acute and chronic
inflammation. In summary, the hybrid compounds provided in the
invention can be useful in treatment of variety of human diseases (i.e.
inflammatory diseases, heart diseases and cancer) with relatively low
level of side effects.
Potential Commercial Applications: The drugs of this invention will
be useful in treatment of anti-inflammatory diseases, and as
therapeutic or preventative drugs for cardiovascular diseases, diabetes
and cancer.
Competitive Advantages: The hybrid structure of the present drugs
will render them useful in therapy and prevention of a wide variety of
disorders, with reduced toxicity.
Development Stage: In vitro data available.
Inventors: David A. Wink et al. (NCI).
Publication: Flores-Santana W et al. Redox-Modified Non-Steroidal
Anti-Inflammatory Drugs as Potential Anti-Cancer Agents with the SOD
Mimetic Nitroxide. Br J Pharmacol. 2011 Jun 9; doi: 10.1111/j.1476-
5381.2011.01527.x (Epub ahead of print). [PMID 21658022].
Intellectual Property: HHS Reference No. E-131-2011/0--U.S.
Provisional
[[Page 76742]]
Application No. 61/472,770 filed 07 Apr 2011.
Licensing Contact: Betty Tong, Ph.D.; (301) 594-6565;
tongb@mail.nih.gov.
Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse
Description of Technology: Scientists at NIDDK have developed a
fibroblast growth factor receptor 1 (Fgfr1) conditional knock out
mouse. Fgfr1 is a member of the Fgfr family of transmembrane protein
receptors with intrinsic tyrosine kinase activity. Fgfr1 is important
in multiple biological processes, including mesoderm induction and
patterning, cell growth and migration, organ formation and bone growth.
Fgfr1 is highly expressed in central nervous system tissues and plays a
critical role in proliferation, migration, and survival of neurons and
glial cells. Additionally, overexpression of Fgfr1 has been associated
with mammary gland transformation and may be crucial for the
development of some cancers. The Fgfr1 conditional knockout mouse can
be used to study development and biological processes in a variety of
tissues and can provide information on signaling pathways that interact
with Fgfr1 to induce genes important for critical cellular events, such
as proliferation, differentiation, adhesion, movement, survival, and
transformation.
Potential Commercial Applications
Basic research tool to investigate intracellular pathways
dependent on Fgfr1.
Tool to study skeletal and neural development.
Model of stress-related environments such as bone
fractures or tumorigenic induction.
Competitive Advantages
Unlike Fgfr1 null mice that are embryonic lethal, Fgfr1
conditional knockout mice are viable and can be used to study the role
of Fgfr1 in tissue and organ development.
Mice carrying the Fgfr1 conditional knockout mutation can
be cross-bred using, for example, Cre-expressing mice to generate
tissue specific knockouts of Fgfr1 and used for more detailed tissue
studies of Fgfr1 signaling.
Development Stage: In vivo data available (animal).
Inventor: Chu-Xia Deng (NIDDK).
Publication: Xu X, Qiao W, Li C, Deng CX. Generation of Fgfr1
conditional knockout mice. Genesis. 2002 Feb;32(2):85-86. [PMID
11857785].
Intellectual Property: HHS Reference No. E-071-2011/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime M. Greene; (301) 435-5559;
greenejaime@mail.nih.gov.
Biomarkers for Cancer-Related Fatigue and Their Use in the Management
of Such Fatigue (CRF)
Description of Technology: The invention relates to the diagnosis
and management of cancer-related fatigue (CRF). More specifically the
invention relates to identification and measurement of a single
Biomarker or a group of biomarkers (e.g. genes) that are associated
with cancer related fatigue. The identification and measurement of such
biomarkers can be utilized in the diagnosis and management of fatigue
and may facilitate the development of therapy for such fatigue. In
particular, the invention provides for a method of diagnosing a subject
with CRF by detecting expression of at least one gene associated with
CRF in a sample obtained from the subject; and comparing expression of
the gene to a control. The invention also describes a method of
treating a patient with CRF by administering to the subject an agent
that alters expression or activity of a gene associated with CRF.
Further provided in the invention is array that includes a plurality of
genes associated with CRF, such as TNFRSF25, SLC6A8, OGT, SNCA, APBA2,
CASK, OR2W3, MYL4, IL7R, ARHGEF10 and ITGA6. Some of these genes are
over expressed in a CRF patient (e.g., SNCA and SLC6A8) while others
(e.g., IL7R, ARHGEF10) are under expressed. The array can provide
detailed and comprehensive information that can result in improved
diagnostics and in increased options for therapeutic treatment.
Potential Commercial Applications: Diagnostics and therapeutics of
cancer-related fatigue.
Competitive Advantages: The technology provides for an array of
multiple biomarkers, all associated with CRF. Thus it may offer a more
detailed and accurate diagnosis of CRF as well as a larger number of
therapeutic options.
Development Stage
In vitro data available (animal).
In vivo data available (human).
Inventor: Leorey Saligan (NINR).
Intellectual Property: HHS Reference E-280-2010/0 -- U.S.
Provisional Application No. 61/442,605 filed 14 Feb 2011.
Licensing Contact: Betty Tong, Ph.D.; (301) 594-6565;
tongb@mail.nih.gov.
Characterizing Compartment Distributions From Diffusion Weighted
Magnetic Resonance (MR) Data
Description of Technology: The National Institutes of Health seeks
licensees with MR software expertise to commercialize a method of
imaging the structural and dimensional characteristics (microstructure)
of microscopic specimens. Microstructure is elucidated using MR
scanning and the diffusion weighted MR signal is transformed into
statistical moments of the underlying compartment size distribution
associated with restricted diffusion. Essentially, the method includes
the steps of: (1) Acquiring diffusion weighted image or spectroscopic
data, (2) applying the new modeling framework relating pore size
distribution to the diffusion weighted (DW) data, and (3) using this
framework to estimate moments of the pore diameter distribution from
the DW data.
Potential Commercial Applications: Examination of tissue/cellular
microstructures.
Competitive Advantages: Refined imaging.
Development Stage: In vitro data available.
Inventors: Evren Ozarslan and Peter J. Basser (NICHD).
Publications
1. Assaf Y, et al. AxCaliber: a method for measuring axon
diameter distribution from diffusion MRI. Magn Reson Med. 2008
Jun;59(6):1347-1354. [PMID 18506799].
2. Shemesh N, et al. Accurate noninvasive measurement of cell
size and compartment shape anisotropy in yeast cells using double-
pulsed field gradient MR. NMR Biomed. 2011 July 22. E-pub ahead of
print, doi: 10.1002/nbm.1737. [PMID 21786354].
3. Ozarslan E, et al. NMR characterization of general
compartment size distributions. New J Phys. 2011 Jan;13:15010. [PMID
21709780].
4. Komlosh ME, et al. Pore diameter mapping using double pulsed-
field gradient MRI and its validation using a novel glass capillary
array phantom. J Magn Reson. 2011 Jan;208(1):128-135. [PMID
21084204].
5. Nevo U, et al. A system and mathematical framework to model
shear flow effects in biomedical DW-imaging and spectroscopy. NMR
Biomed. 2010 Aug;23(7):734-744. [PMID 20886564].
6. Shemesh N, et al. From single-pulsed field gradient to
double-pulsed field gradient MR: gleaning new microstructural
information and developing new forms of contrast in MRI. NMR Biomed.
2010 Aug;23(7):757-780. [PMID 20690130].
7. Shemesh N, et al. Noninvasive bipolar double-pulsed-field-
gradient NMR reveals signatures for pore size and shape in
polydisperse, randomly oriented, inhomogeneous porous media. J Chem
Phys. 2010 Jul 28;133(4):044705. [PMID 20687674].
[[Page 76743]]
Intellectual Property: HHS Reference No. E-273-2010/0--U.S.
Provisional Patent Application No. 61/522,421 filed 11 Aug 2011.
Related Technologies
HHS Reference No. E-079-2003/0--U.S. Patent 7,643,863
issued 05 Jan 2010; International Patent Application PCT/US2004/22027
filed 08 Jul 2004, which published as WO 2005/012926 on 10 Feb 2005.
HHS Reference No. E-079-2003/1--U.S. Patent Application
12/114,713 filed 02 May 2008.
Licensing Contact: Michael Shmilovich, Esq.; (301) 435-5019;
mish@codon.nih.gov.
One Step Fluorine-18 Peptide Labeling Strategy of Biological Substrates
Description of Technology: A one-step process is now available for
licensing that allows direct 18F labeling of any biological substrate
that is modified with 4-nitro-3-trifluoromethyl arene. Normally, 18F
labeling requires several time-consuming radio synthesis steps using
prosthetic groups, resulting in a low labeling yield. Other attempts at
one step labeling methods have also shown relatively low yields.
This new process eliminates time-consuming radiosynthesis steps and
associated low labeling yields with a single step process that
displaces a nitro group in an arene. Relatively low amounts of
precursor and short time radiosynthesis times are required compared to
direct peptide-labeling. Higher yields by this simplified process
improve time and cost efficiencies and may make 18F labeling more
amenable for automation.
Potential Commercial Applications
Radiological imaging.
Radiological diagnosis.
Radiological therapy.
Competitive Advantages
Significantly shorter reaction and synthesis times.
Lower amounts of precursor required.
Relatively high yield of specific activity product.
Development Stage
Early-stage.
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Xiaoyuan (Shawn) Chen and Orit J. Weiss (NIBIB).
Publication: Jacobson O, et al. Rapid and simple one-step F-18
labeling of peptides. Bioconjug Chem. 2011 Mar 16;22(3):422-428. [PMID
21338096].
Intellectual Property: HHS Reference No. E-238-2010/0--U.S.
Provisional Patent Application No. 61/429,671 filed 04 Jan 2011.
Licensing Contact: Tedd Fenn; (301) 435-5031; Tedd.Fenn@NIH.gov.
Collaborative Research Opportunity: The NIBIB is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize the technology
for One Step Fluorine-18 Peptide Labeling Strategy of Biological
Substrates. For collaboration opportunities, please contact Shawn Chen,
Ph.D. at shawn.chen@nih.gov.
Dated: December 2, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-31553 Filed 12-7-11; 8:45 am]
BILLING CODE 4140-01-P
